- Home
- AOMR vs SCPH Comparison
AOMR vs SCPH Comparison
Compare AOMR & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- SCPH
- Stock Information
- Founded
- AOMR 2018
- SCPH 2013
- Country
- AOMR United States
- SCPH United States
- Employees
- AOMR N/A
- SCPH N/A
- Industry
- AOMR Real Estate Investment Trusts
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- AOMR Real Estate
- SCPH Health Care
- Exchange
- AOMR Nasdaq
- SCPH Nasdaq
- Market Cap
- AOMR 240.9M
- SCPH 274.7M
- IPO Year
- AOMR 2021
- SCPH 2017
- Fundamental
- Price
- AOMR $9.85
- SCPH $4.39
- Analyst Decision
- AOMR Buy
- SCPH Strong Buy
- Analyst Count
- AOMR 6
- SCPH 1
- Target Price
- AOMR $11.70
- SCPH $18.00
- AVG Volume (30 Days)
- AOMR 106.3K
- SCPH 318.9K
- Earning Date
- AOMR 11-05-2024
- SCPH 11-06-2024
- Dividend Yield
- AOMR 12.98%
- SCPH N/A
- EPS Growth
- AOMR N/A
- SCPH N/A
- EPS
- AOMR 1.97
- SCPH N/A
- Revenue
- AOMR $69,248,000.00
- SCPH $24,048,000.00
- Revenue This Year
- AOMR N/A
- SCPH $195.62
- Revenue Next Year
- AOMR $30.57
- SCPH $145.07
- P/E Ratio
- AOMR $5.01
- SCPH N/A
- Revenue Growth
- AOMR N/A
- SCPH 549.77
- 52 Week Low
- AOMR $7.85
- SCPH $3.24
- 52 Week High
- AOMR $13.32
- SCPH $6.71
- Technical
- Relative Strength Index (RSI)
- AOMR 31.11
- SCPH 46.35
- Support Level
- AOMR $9.83
- SCPH $3.81
- Resistance Level
- AOMR $10.07
- SCPH $4.50
- Average True Range (ATR)
- AOMR 0.16
- SCPH 0.24
- MACD
- AOMR 0.02
- SCPH 0.03
- Stochastic Oscillator
- AOMR 7.46
- SCPH 70.73
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rates and credit cycles.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.